Anti Inflammatory News and Research

RSS

InSite Vision to advance new development candidate ISV-303

InSite Vision Incorporated, a company developing ophthalmic products for unmet eye care needs, today announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery.

16 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

RORalpha protein revealed as an essential regulator of inflammatory factors

How do the brain cells called astrocytes ensure the protection of neurons? By studying the protagonists in the protection and satisfactory functioning of neurons, scientists at the Laboratoire Neurobiologie des Processus Adaptatifs (CNRS/UPMC) have found a mechanism that clarifies the role of astrocytes.

15 Dec 2009

Myrrh resin may have cholesterol-lowering properties

Laboratory experiments suggest that the resin of certain trees of the Middle East, known commonly as the "myrrh" of the Christmas story, may have cholesterol-lowering properties.

14 Dec 2009

GP Publishing releases "The Miracle of ViaViente"

GP Publishing has just released "The Miracle of ViaViente," authored by world renowned medical journalist Dr. Morton Walker.

10 Dec 2009

Vitamin K2 in Hawaiian Spirulina Pacifica

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced its Hawaiian Spirulina Pacifica® has achieved another nutritional first. Already the most nutritious Spirulina in the world, it is also a good source of Vitamin K2.

10 Dec 2009

Low doses of lidocaine given intravenously help control pain after ambulatory surgery procedures

Although lidocaine is most often used as a local anesthetic, low doses of lidocaine given intravenously can help to control pain after common ambulatory surgery procedures, suggests a study in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

10 Dec 2009

Smokers taking the Respiragene test try to quit smoking, reveals study

Smokers who see their own personal risk of developing lung cancer after genetic-based testing show stronger intention and take more action on quitting smoking, according to clinical trial results presented to an American Association of Cancer Research conference.

9 Dec 2009

New guidelines on the management of antithrombotic agents for endoscopic procedures published

According to a new guideline from the American Society for Gastrointestinal Endoscopy (ASGE) regarding the management of antithrombotic agents for endoscopy, aspirin and/or NSAIDs may be continued for all elective endoscopic procedures.

9 Dec 2009

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.

9 Dec 2009

Arcadia Biosciences' SONOVA 400 receives FDA approval as a dietary supplement ingredient

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the U.S. Food and Drug Administration (FDA) regulatory process for SONOVA™ 400.

8 Dec 2009

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).

8 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

Statins may protect against GVHD complications

Cholesterol-lowering drugs known as statins are among the most prescribed medicines in the U.S. Now a new study by researchers at Fred Hutchinson Cancer Research Center indicates that statins may protect stem cell transplant patients from one of the most serious complications of the life-saving cancer therapy: graft-versus-host disease, or GVHD.

5 Dec 2009

Statins may help protect stem cell transplant patients from GVHD

5 Dec 2009

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone.

3 Dec 2009

Lunasin may have important health benefits, two new studies report

Two new University of Illinois studies report that lunasin, a soy peptide often discarded in the waste streams of soy-processing plants, may have important health benefits that include fighting leukemia and blocking the inflammation that accompanies such chronic health conditions as diabetes, heart disease, and stroke.

3 Dec 2009

Javelin Pharmaceuticals submits an NDA for Dyloject Injection

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, for the management of acute moderate-to-severe pain in adults.

2 Dec 2009

Worldwide DRTV marketing of BioElectronics' ActiPatch and Allay brands

BioElectronics Corp., the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the details of its worldwide Direct Response Television (DRTV) strategy to further enhance its international marketing efforts for its award-winning, pain relieving ActiPatch and Allay brands. The Company will launch campaigns in Latin America beginning in December, Canada in January, Europe and Australia in the first quarter and is currently in process of negotiating a partnership to enter the lucrative Japanese market.

2 Dec 2009

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Novartis announced today that new data, including a late-breaking presentation on Tasigna® (nilotinib) 200 mg capsules in a form of chronic myeloid leukemia, demonstrate the strength of the company's hematology portfolio in advancing the care of patients.

2 Dec 2009

Anti Inflammatory News and Research

InSite Vision to advance new development candidate ISV-303

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

RORalpha protein revealed as an essential regulator of inflammatory factors

Myrrh resin may have cholesterol-lowering properties

GP Publishing releases "The Miracle of ViaViente"

Vitamin K2 in Hawaiian Spirulina Pacifica

Low doses of lidocaine given intravenously help control pain after ambulatory surgery procedures

Smokers taking the Respiragene test try to quit smoking, reveals study

New guidelines on the management of antithrombotic agents for endoscopic procedures published

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

Arcadia Biosciences' SONOVA 400 receives FDA approval as a dietary supplement ingredient

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

New approach to protein misfolding may lead to novel therapies for a number of diseases

Statins may protect against GVHD complications

Statins may help protect stem cell transplant patients from GVHD

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Lunasin may have important health benefits, two new studies report

Javelin Pharmaceuticals submits an NDA for Dyloject Injection

Worldwide DRTV marketing of BioElectronics' ActiPatch and Allay brands

New data demonstrating the strength of Novartis' hematology portfolio to be presented

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News